Fuji Pharma buys darbepoetin alfa from South Korean company

Japanese pharma company Fuji Pharma recently in licensed darbepoetin alfa, a bone marrow stimulant, from Chong Kun Dang Pharmaceutical, a Seoul-based company, for subsequent development and commercialization in Japan. Financial details of the transaction are not disclosed.

“In Japan, darbepoetin alfa is widely used to improve renal anemia for hemodialysis patients   and patients with non-dialysis chronic kidney disease,” a Fuji Pharma spokesperson told the Pharma Letter’s correspondent Wang Fangqing.

She said the deal is in line with Fuji’s new five-year strategy “Fuji Pharma Branding” initiated in 2015, which aims to establish a model that combines proprietary drugs, generics/biosimilars and contract manufacturing.